Genomind, a leading mental health care company, is launching Genomind Professional PGx Express™, a new, more focused report and set of services to enhance its mental health genetic test. Genomind Professional PGx Express will provide clinical professionals with the most current, science-backed information and includes consultations upon request to help them navigate the connection between an individual’s genetic biomarkers and their implications for mental health treatment.
The company opted to launch Genomind Professional PGx Express in response to positive clinician feedback, growing demand in the market, and recent U.S. Food and Drug Administration requests to laboratories performing pharmacogenomic (PGx) testing to remove any mentions of medications or drug classes from PGx reporting. Signaling the growing acceptance for PGx mental health testing, UnitedHealthcare has issued a positive coverage decision for the use of multi-gene panel PGx testing, including Genomind’s service, in certain consumers being treated for major depressive disorder (MDD) or anxiety.
Genomind Professional PGx Express genetic test services will quickly provide the important information in an individual’s genetic profile. In addition, new technology and consultative services enable access to resources to help medical providers understand the implications of these genetic biomarkers. In analyzing 24 genes associated with mental health, Genomind Professional PGx Express provides the most comprehensive mental health genetic test results available.
Via a painless cheek swab administered in the physician’s office, Genomind Professional PGx Express collects information on 24 well-characterized, well-annotated genes, making it the most comprehensive mental health genetic test available. Genomind Professional PGx Express supports the genetic profile implications for the treatment of mental health disorders including: depression, anxiety, autism, schizophrenia, chronic pain, bipolar disorder, obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), and substance abuse.
Genomind is a leading mental health care company, delivering the genetic testing tools designed to empower clinicians to make better informed treatment decisions and create better outcomes for consumers with mental illnesses. As the scientific leader in genetic testing, Genomind’s flagship offering is Genomind Professional PGx Express–the most comprehensive mental health genetic service available. Supported by a world-class genetics lab and unique consultative approach, Genomind is advancing a new paradigm of personalized medicine in mental health care.
This was reported by Genomind on August 5, 2019.
Contact information: Amy Pressman, Marketing Director, Genomind, 2200 Renaissance Boulevard, Suite 100, King of Prussia, Pennsylvania 19406; 877-895-8658; Email: email@example.com; Website: http://genomind.com